Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
7
×
life sciences
zolgensma
7
×
biotech
boston top stories
gene therapy
national blog main
national top stories
new york blog main
new york top stories
novartis
clinical trials
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
spinal muscular atrophy
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
deals
glaxosmithkline
johnson & johnson
startups
abbvie
amgen
What
roundup
bio
biotech
news
drug
gene
healthcare
long
nash
past
public
remains
therapy
according
age
akcea
america
approval
august
bigger
biggest
biogen
biogen’s
biopharmaceutical
busy
cases
centers
cigarettes
come
companies
continues
control
convo
convoluted
crude
cutting
days
deal
deaths
decisions
Language
unset
Current search:
zolgensma
×
" boston blog main "
×
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy